Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Commonly Used Medications on Mood and Choice
NCT03652740Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Oct 2018
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of caffeine, methylphenidate hydrochloride extended-release chewable tablet and nicotine in substance use disorder (SUD) (2 arms), sponsored by Johns Hopkins University. Primary endpoint: Participant Subjective Ratings of Drug Liking (Peak Change) up to 4 hours. Started Oct 2018; status: completed.
02
Drugs
caffeinemethylphenidate hydrochloride extended-release chewable tabletnicotine
03
Conditions
substance use disorder (SUD)
Beyond the preview
Go deeper on NCT03652740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652740.